ASXC asensus.com: Koefisien utang jangka dawa marang modal

Asensus Surgical, Inc. (ASXC) develops innovative Senhance robots for minimally invasive interventions, and the acquisition by tech giant KARL STORZ at $0.35 per share has neutralized default risks. This price chart links these events to revenues generated from the sale of AI systems for laparoscopy and ancillary services. Diversification of electronics suppliers eliminates assembly disruptions, and the current metric stands at 0.00, confirming the resilience of the operating model.

This ratio determines the proportion of long-term debt obligations relative to the company's equity. Investors utilize this metric to assess financial stability and the extent of the business's reliance on external borrowing. By analyzing the long-term debt-to-equity structure, one can identify the balance between bankruptcy risks and expansion rates. For Asensus Surgical, Inc. (ASXC), this indicator reflects the cost of the ambitious implementation of AI systems in surgery. An optimal value confirms management's ability to fund the digitalization of laparoscopy without a critical debt burden.